The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00159861
First received: September 8, 2005
Last updated: December 20, 2013
Last verified: December 2013
  Purpose

Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension


Condition Intervention Phase
Pulmonary Hypertension
Drug: Sildenafil citrate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Categorized Change From Baseline in 6-Minute Walking Distance [ Time Frame: 1 Year, 2 Year, 3 Year ] [ Designated as safety issue: No ]
    Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing.


Secondary Outcome Measures:
  • Survival Status [ Time Frame: 1, 2, 3, 4, and 5 years ] [ Designated as safety issue: Yes ]
    Yearly survival status: number of subjects who survived, discontinued, and died. Analysis includes post-treatment visit data from subjects who discontinued study treatment. Time to death was taken relative to the first dose of study treatment in A1481141, and was censored on the last day the subject was known to be alive in A1481141 or A1481153.

  • Change in Pulmonary Hypertension Criteria for Functional Capacity and Therapeutic Class [ Time Frame: 1 Year, 2 Year, 3 Year ] [ Designated as safety issue: No ]
    Pulmonary hypertension (PH) criteria: Class I: PH without limitation of physical activity (PA) (no undue dyspnea, fatigue, chest pain, near syncope); Class II: PH with slight limitation in PA, comfortable at rest, ordinary PA causes undue dyspnea, fatigue, chest pain, near syncope; Class III: PH with marked limitation in PA, comfortable at rest, less than ordinary activity causes undue dyspnea, fatigue, chest pain or syncope; Class IV: PH with inability to carry out PA without symptoms, signs of right heart failure, dyspnea or fatigue may be present at rest, discomfort increased by any PA.

  • Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36) [ Time Frame: Baseline, Month 15, Month 27, Month 39 ] [ Designated as safety issue: No ]
    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Change from baseline = score at observation minus score at baseline.

  • Change From Baseline in European Quality of Life Scale (EuroQol) 5-Dimensions (EQ-5D): Utility Index Score [ Time Frame: Baseline, Month 15, Month 27, Month 39 ] [ Designated as safety issue: No ]
    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Change From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score [ Time Frame: Baseline, Month 15, Month 27, Month 39 ] [ Designated as safety issue: No ]
    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

  • Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36): Reported Health Transition Score [ Time Frame: Baseline, Month 15, Month 27, Month 39 ] [ Designated as safety issue: No ]
    Subject-rated measure of health status (36 items): 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health), 2 summary scores (physical component, mental component), and a self-evaluated change in health status. Change from Baseline in SF-36 Health Transition score at each visit. I=much better than 1 year ago; II=somewhat better than 1 year ago; III=about the same as 1 year ago; IV=somewhat worse than 1 year ago; V=much worse than 1 year ago

  • Change From Baseline in BORG Dyspnea Score [ Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36 ] [ Designated as safety issue: No ]
    BORG Dyspnea score: change from core study Baseline. Subject rating of maximum degree of dyspnea experienced at any time during the 6-Minute Walk Test. Range: 0 (no breathlessness at all) to 10 (maximum breathlessness).


Other Outcome Measures:
  • Change in Epoprostenol Dose From Baseline Maintained for 6 Months [ Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, and at 3-month intervals through Month 69 ] [ Designated as safety issue: No ]
    Number of subjects with changes in Epoprostenol dose from baseline maintained continuously for 6 months. Increased = Epoprostenol dose continuously more than 20% greater than core study Baseline for at least 6 months. Decrease = Epoprostenol dose continuously more than 20% less than core study Baseline for at least 6 months. No change = Epoprostenol dose change met neither Increase or Decrease criteria. Stopped = Epoprostenol dose stopped for at least 6 months.


Enrollment: 267
Study Start Date: July 2003
Study Completion Date: January 2006
  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion

Exclusion Criteria:

  • PH other than PAH
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159861

  Hide Study Locations
Locations
United States, California
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Los Angeles, California, United States, 90033
Pfizer Investigational Site
Los Angeles, California, United States, 90073
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
Torrance, California, United States, 90502
Pfizer Investigational Site
Torrance, California, United States, 90509
United States, Colorado
Pfizer Investigational Site
Denver, Colorado, United States, 80220
Pfizer Investigational Site
Denver, Colorado, United States, 80262
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
United States, Kansas
Pfizer Investigational Site
Kansas City, Kansas, United States, 66160
United States, Louisiana
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70112
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
Pfizer Investigational Site
Boston, Massachusetts, United States, 02111
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Pfizer Investigational Site
Rochester, Minnesota, United States, 55905
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68105
Pfizer Investigational Site
Omaha, Nebraska, United States, 68198-2125
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10032
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45267-0769
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Pfizer Investigational Site
Providence, Rhode Island, United States, 02903
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-5735
United States, Texas
Pfizer Investigational Site
Houston, Texas, United States, 77030
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84143
United States, Wisconsin
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53215
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53277
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53226
Belgium
Pfizer Investigational Site
Leuven, Belgium, 3000
Canada, Alberta
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1Y 4E9
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1Y 4W7
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 2N2
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1E2
Czech Republic
Pfizer Investigational Site
Prague 2, Czech Republic, 128 08
Denmark
Pfizer Investigational Site
Kobenhavn, Denmark, 2100
France
Pfizer Investigational Site
Clamart Cedex, France, 92141
Pfizer Investigational Site
Grenoble Cedex 09, France, 38043
Pfizer Investigational Site
Vandoeuvre Les Nancy, France
Israel
Pfizer Investigational Site
Petach Tikva, Israel, 49100
Italy
Pfizer Investigational Site
Bologna, Italy, 40138
Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV
Pfizer Investigational Site
Nieuwegein, Netherlands, 3435CM
Spain
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Madrid, Spain, 28041
United Kingdom
Pfizer Investigational Site
Papworth Everard, Cambridgeshire, United Kingdom, CB3 8RE
Pfizer Investigational Site
Glasgow, United Kingdom, G11 6NT
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00159861     History of Changes
Obsolete Identifiers: NCT00147641
Other Study ID Numbers: A1481141
Study First Received: September 8, 2005
Results First Received: April 2, 2010
Last Updated: December 20, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Citric Acid
Sildenafil
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Cardiovascular Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Urological Agents

ClinicalTrials.gov processed this record on September 18, 2014